Visit us on booth 1529 to find out more about the clinical data supporting the use of HIVEC in NMIBC. COMBAT Medical‘s innovative, patented BRS delivers HIVEC to help maximise the efficacy of the chemotherapy installation in the treatment of non-muscle invasive bladder cancer (NMIBC), while remaining simple to integrate into current practice . Over 60,000 treatments have been given to date across 260 + centres in 40 countries. 3 abstracts on HR and BCGF patients treated with HIVEC have been accepted for presentation at AUA, please visit us for further information. The CE marked BRS is not currently FDA approved for use in the USA (with the exception of a specific IND in place at Duke university).
Brands: Combat Medical Ltd